Description
: Planned Biologics License Application (BLA) submission to FDA expected in the second half of 2026; company continues to expect to file the BLA in 2H 2026 with potential FDA approval in 2027. The BLA filing is intended to be supported by the LEGEND pivotal cohort data and SAP agreement with FDA.[3]